Navigation Links
State's First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
Date:8/25/2008

DETROIT, Aug. 25 /PRNewswire/ -- For the first time in Michigan, a diseased kidney has been surgically removed at using highly sophisticated 3D robotics through a single incision.

"We made several improvements in the technique that could allow us to perform this type of procedure routinely," says Craig Rogers, M.D., Henry Ford's director of robotic renal surgery. He performed the delicate operation last week using the da Vinci Surgical System, which has already been used in thousands of successful surgeries for complete and partial removal of diseased prostates.

The kidney, damaged by four tumors, was extracted through an incision of about three inches near the patient's navel of a 50-year-old patient during a complex minimally invasive robotic procedure that lasted approximately 2.5 hours.

The procedure takes its name in part from its minimally invasive approach: SIRS or Single Incision Robotic Surgery.

"We traditionally try to save the kidney for smaller tumors, performing a robotic partial nephrectomy," says Dr. Rogers. "For larger tumors, however, patients would get a very large incision on their side. Now, we can remove kidneys with cancer through a single three-inch incision near the patient's belly button."

The potential benefits to performing the SIRS nephrectomy are improved cosmetics, quicker recovery times, less scarring and blood loss. Dr. Rogers and his colleagues have also pioneered robotic surgery for smaller kidney tumors, allowing them to perform a partial nephrectomy to remove tumors that might otherwise require total kidney removal or a large open incision. While these procedures are considered revolutionary because they preserve the healthy portion of the kidney and shorten recovery time, they are not practical for patients with large tumors.

"I think this is going to be a big advance for having to remove the entire kidney because of large kidney tumors. This could be a great improvement over traditional open and laparoscopic surgeries."

Henry Ford doctors have performed more than 130 robotic kidney surgeries using four or five incisions of less than one inch. When Henry Ford doctors perform robotic surgery with the da Vinci system, a camera and small robotic instruments are inserted through small incisions and controlled by the surgeon from a nearby console machine.

In the SIRS procedure, Dr. Rogers inserts the robotic arms through a single incision near the belly button, and sits at a nearby machine controlling the robot throughout the operation.

"I control every movement made by the robotic arms," says Dr. Rogers. "The robotic instruments are like having my hands inside the body."

Working through the single small incision, the robot-assisted surgeon inflates the abdomen; moves the large intestine aside to reach the kidney; clips or ties off the vein and artery that take blood to and from the kidney; detaches the rest of the kidney, and removes it.

Kidney cancer is diagnosed in approximately 55,000 people a year and the most common treatment option is an open surgery with a large incision about a foot long. Surgeons sometimes must remove a rib, and they must go through muscle to remove the kidney. Recovery can be up to two months with a weeklong hospital stay.

Besides cancer patients, candidates for SIRS nephrectomy include those with nonfunctioning kidneys due to blockage, stones, or congenital abnormalities.

This week's innovative and successful kidney procedure comes after Henry Ford has established itself as the leading facility worldwide for robot-assisted surgical treatment of prostate cancer. More than 4,000 such procedures have been performed by Henry Ford surgeons since 2001.

"We think we'll see the same advantages with robotic kidney surgery as we have with robotic prostatectomy," says Dr. Rogers.


'/>"/>
SOURCE Henry Ford Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
3. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
4. Animetrics Inc. Selected to Provide 3D Face Viewer Technology for United States Army Biometric Automated Toolset (BAT)
5. Genzyme Files Applications for Approval of Mozobil in the United States and Europe
6. Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates
7. Genetic Engineering and Biotechnology News (GEN) Blog: International Students in the United States - A Diminishing Pool of Talent for Biotech?
8. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
9. Unigene Restates Policy on Analyst Reports
10. Moleac Launches NeuroAid10(TM) in the United States
11. United States Patent Office Grants CryoCors Request for Patent Interference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):